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Abstract
Background: Celiac disease (CD) is a chronic, small intestinal inflammatory disease mediated by dietary gluten and
related prolamins. The only current therapeutic option is maintenance of a strict life-long gluten-free diet, which
implies substantial burden for CD patients. Different treatment regimes might be feasible, including masking of
toxic celiac peptides with blocking antibodies or fragments thereof. The objective of this study was therefore to
select and produce a recombinant avian single-chain fragment variable (scFv) directed against peptic-tryptic
digested gliadin (PT-Gliadin) and related celiac toxic entities.
Results: Gluten-free raised chicken of same age were immunized with PT-Gliadin. Chicken splenic lymphocytes,
selected with antigen-coated magnetic beads, served as RNA source for the generation of cDNA. Chicken VH and
VL genes were amplified from the cDNA by PCR to generate full-length scFv constructs consisting of VH and VL
fragments joined by a linker sequence. ScFv constructs were ligated in a prokaryotic expression vector, which
provides a C-terminal hexahistidine tag.
ScFvs from several bacterial clones were expressed in soluble form and crude cell lysates screened for binding to
PT-Gliadin by ELISA. We identified an enriched scFv motif, which showed reactivity to PT-Gliadin. One selected scFv
candidate was expressed and purified to homogeneity. Polyclonal anti-PT-Gliadin IgY, purified from egg yolk of
immunized chicken, served as control. ScFv binds in a dose-dependent manner to PT-Gliadin, comparable to IgY.
Furthermore, IgY competitively displaces scFv from PT-Gliadin and natural wheat flour digest, indicating a common
epitope of scFv and IgY. ScFv was tested for reactivity to different gastric digested dietary grain flours. ScFv detects
common and khorasan wheat comparably with binding affinities in the high nanomolar range, while rye is
detected to a lesser extent. Notably, barley and cereals which are part of the gluten-free diet, like corn and rice, are
not detected by scFv. Similarly, the pseudo-grain amaranth, used as gluten-free alternative, is not targeted by scFv.
This data indicate that scFv specifically recognizes toxic cereal peptides relevant in CD.
Conclusion: ScFv can be of benefit for future CD treatment regimes.
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Background
Celiac disease (CD) is a chronic, small intestinal, immune-
mediated disease driven by dietary wheat gluten and
related prolamins in rye and barley [1, 2]. Disease
hallmarks are varying degrees of villous atrophy, crypt
hyperplasia, intraepithelial lymphocyte infiltrates and
serum auto-antibodies [3]. Although the hellenic physician
Artaeus the Cappadocianin already described CD symp-
toms in the second century AD [4], it was not until the
1940s when the link to dietary prolamins was established
by the Dutch pediatrician Dicke [5, 6]. The current defin-
ition of CD is based on the 14th International CD Sympo-
sium in 2011 which led to ’The Oslo definitions for celiac
disease and related terms’, published by Ludvigsson et al.
in 2013 [6]. Despite all efforts to describe and understand
disease mechanisms, there is still lack of appropriate
treatment. A stringent, life-long gluten free diet (GFD) is
the only option, favoring abatement of symptoms and
improvement of intestinal barrier function in most
CD patients. Some potential treatment agents are
already in preclinical and clinical phases, for example
glutenase ALV003 [7, 8] (clinicaltrials.gov identifier
NCT00959114, NCT01255696) or tight junction regu-
lator larazotide acetate AT-1001 [9] (clinicaltrials.gov
identifier NCT01396213, NCT00620451). Another poten-
tial approach for CD treatment could be the blocking of
toxic dietary peptides by antibodies or fragments thereof,
which was the objective of this study.
Wheat gluten peptides, subdivided dependent on solu-
bility in watery alcohols into soluble gliadins and insoluble
glutenins, represent a heterogeneous mix of proteins of
different molecular weights [10]. Peptic, tryptic digests of
the gliadin fraction, termed PT-Gliadin, mimic the peptide
fraction entering the duodenum after gastric digestion.
PT-Gliadin is a commonly chosen model antigen for
studying CD [11–13] and served therefore as immunogen
for chicken in this study. We produced PT-Gliadin react-
ive chicken yolk antibodies (IgY) and used immunized
chicken as source for the production of recombinant anti-
body fragments in the single-chain format. Chicken IgY
represents the avian equivalent to mammalian IgG,
though IgY has many advantages considering human
applications: IgY exerts no mammalian complement acti-
vation, rheumatoid factor interaction or cross-reactivity
with mammalian IgG [14]. IgY can be easily purified from
yolks of immunized chicken by precipitation [15] or
chromatography methods [16]. In principle, IgY can be
administered orally in enteric coated form [17, 18].
Chicken IgY is described for different diagnostic and
therapeutic applications [19–22], including anti-Gliadin
IgY for CD treatment [23]. However, we consider the use
of yolk IgY inefficient for clinical large scale production.
Thus our goal was to engineer IgY fragments in a recom-
binant format, which can be expressed in Escherichia coli
(E. coli) in soluble form and offers a scalable production
process. In this study we report the cloning and selection
of an avian single-chain fragment variable (scFv) directed
against PT-Gliadin. We present data demonstrating the in
vitro potential of scFv in targeting PT-Gliadin and natural
flour digests. We observed comparable binding character-
istics for scFv and polyclonal yolk IgY.
Methods
Preparation of PT-Gliadin
PT-Gliadin was prepared from wheat gliadin (Sigma)
according to previously described methods [24] with
some adjustments. Briefly, 10 g gliadin (gliadin from
wheat, Sigma-Aldrich) was subjected to 40 ml 20 mM
sodium acetate buffer, pH 4.5. 800 μl immobilized pepsin
(Thermo Scientific), washed three times with sodium
acetate buffer according to manufacturer’s instruction,
was added to the gliadin-buffer mixture. Peptic digest
was performed by overnight incubation at 37 °C with
agitation at 350 rpm. Pepsin was separated by centrifu-
gation at 4000 x g for 2 min and aspiration of the super-
natant. Pepsin was regenerated and stored according to
manufacturer’s instruction. The supernatant was ad-
justed to pH 8 with 1 N NaOH. 800 μl immobilized
trypsin (Thermo Scientific), washed three times with
20 mM ammonium hydrogen carbonate according to
manufacturer’s instruction, was added to the gliadin
digest. Tryptic digest was performed by overnight incu-
bation at 37 °C with agitation. The volume was adjusted
with ammonium hydrogen carbonate to 45 ml and the
mixture incubated for further 3 h at 37 °C. Trypsin was
separated by centrifugation at 4000 x g for 2 min and
aspiration of the supernatant. Trypsin was regenerated
and stored according to manufacturer’s instruction. The
supernatant (containing PT-Gliadin) was filtrated through
fluted and subsequently through 0.45 μm syringe fil-
ters. Total protein content was measured by BCA test
(Pierce™ BCA Protein Assay Kit, Thermo Scientific)
and PT-Gliadin was lyophilized to equal protein
amounts (~8 mg/ml) and stored at 4 °C. When
needed, PT-Gliadin was resuspended in 1 ml sterile
Tris buffered saline (TBS, made from 10 x concentrate,
Sigma) and total protein content was confirmed by BCA
measurement. For the immunization of chicken, PT-
Gliadin was resuspended in 10 % acetic acid.
Preparation of flour digests
100 mg NaCl (Sigma-Aldrich) and 160 mg pepsin were
dissolved in 25 ml H2O, pH was adjusted to 1.2 with
1 M HCl and volume was adjusted to 50 ml with H2O.
This solution mimics gastric digestion and is referred to
as simulated gastric fluid (SGF) according to United
States Pharmacopoeia (USP32-NF27).
Stadlmann et al. BMC Biotechnology  (2015) 15:109 Page 2 of 14
Barley (Rollgerste Gerstengraupen, Alnatura) and
amaranth (Bio Amaranth “Das Inka-Korn”, HOLO)
grains were grinded with mortar and pestle and 1 g
of the grist was subjected to 5 ml SGF according to
the protocol for flours described below. Wheat flour
(Bio Weizen Vollkornmehl, Ja! Natürlich), khorasan
wheat flour (Bio Kamutmehl, Vollkraft), rye flour (Bio
Roggen Vollkornmehl, Rosenfellner Mühle), rice flour
(Bio Reismehl fein gemahlen, HOLO), and corn flour
(Polenta, Fini’s Feinstes,) were subjected directly to
SGF: 5 ml SGF was added to 1 g flour or grist and
incubated for 1 h at 37 °C with agitation at 350 rpm.
Pepsin was separated by centrifugation at 14,800 x g
for 4 min and aspiration of the supernatant. Pepsin
was regenerated and stored according to manufac-
turer’s instructions. Supernatant (resembling the flour
digest) was adjusted to pH 8 with 1 N NaOH and
the end volume was adjusted to 8 ml.
Immunization of laying hens
Brown laying hens, Gallus gallus domesticus Tetra SL,
were raised on a gluten free diet from day 1 after hatch-
ing. Hens were primary immunized at an age of eight
weeks by injecting a mixture of 250 μg PT-Gliadin (dis-
solved in 10 % acetic acid) and adjuvant into the pectoral
muscle. Booster immunizations were given in intervals
of three to four weeks. Blood samples were drawn pre and
in weekly intervals after immunization and stored in 10 %
EDTA at – 20 °C until analysis. All animal procedures
followed the institutional laboratory animal research
guidelines and were approved by the State veterinary and
food administration of the Slovak republic.
Anti-PT-Gliadin-IgY
60 eggs collected from various immunized chicken
housed in the same facility were pooled to an IgY batch.
IgY fraction was precipitated from egg yolks according
to a previously developed in-house method: Yolks were
separated from egg white and mixed with the 9-fold
amount of deionized H2O with respect to yolk weight.
3 ml caprylic acid, pH 4.0 (Merck), per egg yolk was
added drop-wise and the solution stirred for 1 h.
Solution was filtered through fluted filter and washed
with 30 ml deionized-H2O per egg yolk. Filter cake was
discarded and the pH of the solution was adjusted to 7.2
with 1 N NaOH. 20 % (v/v) pre-chilled ethanol (Ethanol
absolute, Roth) was added slowly under constant stirring
at 400 rpm (volume ethanol represent ¼ of volume
caprylic acid precipitation). Solution was precipitated
over night in centrifuge beakers at −10 °C, followed by a
centrifugation step at 0 °C and 11,000 x g for 30 min.
Supernatant was discarded, pellet was dissolved in 15 ml
phosphate buffer saline (PBS) and stored at −20 °C until
use. 12 ml of the resuspended solution was subjected to
12 ml 10 mM phosphate buffer supplemented with
100 mM NaCl. 3.5 % (w/v) polyethylene glycol 6000
(PEG, Sigma-Aldrich) was added and mixture stirred at
400 rpm for 30 min at room temperature. Solution was
centrifuged at 13,000 x g for 10 min and the supernatant
was filtered through a fluted filter. 12 % (w/v) fresh PEG
6000 was added and the mixture stirred at 400 rpm for
1 h at room temperature. Solution was centrifuged at
13,000 x g for 10 min. The supernatant was discarded
and the pellet was resuspended in a total volume of
12 ml 10 mM phosphate buffer supplemented with
100 mM NaCl. 12 % (w/v) fresh PEG 6000 was added
and the mixture stirred at 400 rpm for 1 h at room
temperature. Solution was centrifuged at 13,000 x g for
10 min. The supernatant was discarded and the centrifu-
gation step, discarding the supernatant, repeated twice.
The pellet containing the purified IgY fraction was resus-
pended in TBS and stored at 4 °C until use.
Cloning strategy for the generation of chicken scFvs
10–14 days after the third immunization, chicken with
confirmed blood titer were sacrificed. Spleens were har-
vested and merged through a 100 μm nylon cell strainer
(BD Biosciences) with 10 ml sterile phosphate buffered sa-
line (PBS sterile, Life Technologies). 10 ml sterile ficoll so-
lution (GE Healthcare) was pipetted underneath the cell
suspension and tubes were centrifuged at 660 x g for
20 min for the formation of a density gradient. The inter-
phase, containing mononuclear cells (lymphocytes and
monocytes, respectively) was isolated, and the remaining
gradient discarded. Mononuclear cells were washed with
1 ml fresh PBS, mixed be inverting the tube and centri-
fuged at 300 x g for 5 min. Supernatant was discarded and
the washing step was repeated twice. Washed cells were
diluted in PBS to a concentration of 1 x 10^7 cells/ml and
afterward subjected to magnetic beads (Dynabeads M-450
Epoxy, Life Technologies), pre-coated with PT-Gliadin ac-
cording to manufacturer’s instructions. 25 μl of pre-coated
beads were washed according to protocol and added to
1 ml cell suspension. Suspension was incubated at 4 °C
with end-over-end tilting for 20 min. Suspension was
placed on a magnetic stand for 2 min, supernatant was
discarded. Beads bound cells were washed six times with
fresh, sterile PBS. PBS was discarded and beads bound
cells were resuspended in 1 ml PBS. Beads bound cells
were subjected immediately to total RNA extraction using
ReliaPrep™ RNA Cell Miniprep System from Promega ac-
cording to manufacturer’s instruction. Beads were
separated magnetically prior to loading of the suspension
on the RNA capturing mini column. RNA quantity was
analyzed by NanoDrop 2000c spectrophotometer (Peqlab
biotechnology GMBH). Complementary DNA (cDNA)
was synthesized from ~1 μg total RNA using random hex-
americ primers (Life technologies) and SuperScript®III
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First-Strand Synthesis System (Life technologies) accord-
ing to manufacturer’s instructions. cDNA was amplified
using a set of specific primers for chicken VH (forward:
5′-GCC GTG ACG TTG GAC GA-3′; reverse: 5′-GGA
GGA GAC GAT GAC TTC GG-3′) and VL (forward: 5′-
AGG CTG ACT CAG CCG T-3′; reverse: 5′-ACC TAG
GAC GGT CAG GG-3′) gene regions. Gel purified PCR
products were subjected to a second PCR reaction, to
introduce a peptide linker (GSTSGSGKPGSGEGSTKG)
sequence [25] and restriction sites:
VH gene products were amplified with primer sets to
introduce NcoI/BamHI sites (forward: 5′-ATG TCT
CTA TCC ATG GCC GTG ACG TTG GAC GA-3′;
NcoI site in boldface; reverse:
5′-ATG ATG GGA TCC GGG CTT GCC GCT ACC
GGA AGT AGA GCC GGA GGA GAC GAT GAC
TTC GG-3′, BamHI site in boldface;). VL gene products
were amplified with primer sets to insert BglII and NotI
sites (forward: 5′- CAT CAT AGA TCT GGT GAA
GGT AGC ACT AAA GGT GCG CTG ACT CAG CCG
T-3′, BglII site in boldface; reverse: 5′- GTG GTG GTG
CTC TCG AGT GCG GCC GCG GGA CCT AGG
ACG GTC AGG G-3′, NotI site in boldface). VH and VL
re-amplification products were directly used for cloning
into pCR® 2.1 by TOPO cloning (TOPO®, Life technolo-
gies) according to manufacturer’s recommendation.
50 μl of chemically competent Escherichia coli (E. coli)
One Shot® TOP10 (Life technologies) were transformed
with 2.5 μl of TOPO VH or VL cloning products, re-
spectively. Bacterial clones were grown overnight in
2 ml LB broth (Sigma) supplemented with 50 μg/ml
ampicillin at 225 rpm at room temperature. Plasmid
DNA from overnight cultures was isolated using Pure
Yield™ Plasmid Mini Prep System from Promega.
Plasmid DNA was subjected to sequencing using
M13_rev sequencing primer (5′-CAG GAA ACA GCT
ATG AC-3′) at Microsynth AG, Vienna, Austria.
Sequencing analysis ensured the correct insertion of VH/
VL cloning products; at least four clones per plate were
analyzed. To generate separate chicken VH and VL li-
braries, TOPO VH or VL cultures were scraped off the
plates and transferred to 100 ml fresh LB broth (supple-
mented with 50 μg/ml ampicillin) each. Library cultures
were incubated overnight at 225 rpm and 37 °C. Plasmid
DNA of VH and VL library cultures was isolated with
Pure Yield™ Plasmid Midiprep System from Promega.
DNA concentration was quantified photometrical (Bio-
Photometer, dsDNA method, Eppendorf ). VH Plasmid
DNA (corresponding to 5–10 μg DNA) was subjected to
digestion with NcoI and BamHI (New England BioLabs),
while VL Plasmid DNA was digested with NotI and BglII
(New England BioLabs). The plasmid vector pET28a(+)(-
Novagen) was digested with NcoI and NotI, followed by
dephopsphorylation with alkaline phoshatase (Roche).
Restriction digests were separated by preparative 1.2 %
agarose gels and VH and VL bands isolated from the gel
with sterile scalpels and purified using QIAEX II Gel
Extraction Kit (Qiagen). A 3-way ligation of VH and VL
fragments and pET28a(+) expression vector (carrying a
His6-tag) was performed to generate full-length scFvs: E.
coli One Shot® BL21(DE3) (Life technologies) were trans-
formed with the ligation products. As quality control, at
least four clones per plate were cultivated overnight as
mentioned above and analyzed by sequencing with
pET28a_seq forward (5′-GTC CGG CGT AGA GGA
TCG-3′) and reverse (5′-ATC CGG ATA TAG TTC CTC
CTT T-3′) primers, to ensure the insertion of correct
full-length scFvs in-frame with the C-terminal hexa-
histidine tag.
Soluble expression of His6-tagged-scFvs in E. coli BL21 (DE3)
Individual bacterial clones were cultivated in LB supple-
mented with 25 μg/ml of kanamycin (kanamycin sulfate,
Sigma-Aldrich) with agitation at 225 rpm over night at
room temperature. The next day, fresh LB medium (sup-
plemented with 25 μg/ml of kanamycin) was inoculated
with 1/10 volume of overnight culture. Expression
cultures were cultivated at room temperature with
agitation at 225 rpm until optical density (OD)600
reached 0.4 – 0.5. Protein expression was induced by the
addition of 1 mM sterile isopropyl ß-D-1-thiogalactopy-
ranoside (IPTG, Sigma-Aldrich) to expression cultures. At
selected time points pre- and post induction, cell pellets
were harvested by centrifugation at 2000 x g for 20 min.
Supernatants were discarded and cell pellets stored frozen
at −80 °C until cellular lysis. Cell pellets were lysed with
Qproteome™ Bacterial Protein Prep Kit from Qiagen ac-
cording to manufacturer’s instruction. The soluble superna-
tants, referred to as crude extracts, were stored at −20 °C.
Purification of anti-PT-Gliadin scFv
Small-scale purification of bacterial crude extracts was per-
formed using Ni-NTA-spin columns (Thermo Scientific:
0.2 ml or 10 ml volumes respectively) according to manu-
facturer’s instructions. Eluates were buffer exchanged in
TBS using Zeba Spin Desalting Columns (Thermo
Scientific, 7 K MWCO, 0.5 ml or 10 ml volumes respect-
ively) according to manufacturer’s instructions. Purified
proteins were stored at −20 °C. For large scale expression,
scFv was cultivated in LB supplemented with 25 μg/ml of
kanamycin in lab fermenter scale (1–5 l culture volume re-
spectively). Protein expression was induced with 1 mM
IPTG and cell pellets were harvested 4–5 h post induction
by centrifugation at 2000 x g for 20 min. Cell pellets were
resuspended in 10 mM imidazole buffer (3–4 buffer excess
in relation to wet biomass). Solution was treated three
times for 30 s with an ultra-turaxx on ice. Solution was ho-
mogenized for 5 min 15 s at 100–150 MPa on ice (for
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20 ml volumes respectively). Homogenizates, containing
soluble ScFv, were purified by Immobilized Metal Affinity
Chromatography (IMAC) with HiTrap TALON crude col-
umns (1 or 25 ml size, Co2+) and imidazole (10 mM imid-
azole in application buffer, 500 mM imidazole in elution
buffer) using an äkta purifier (Äkta pure, GE Healthcare).
IMAC eluates were further purified by Size-Exclusion-
Chromatography (Superdex 75 pg, Mr 3 000 to 70 000. 16/
600, GE Healthcare) using an äkta purifier (Äkta pure, GE
Healthcare). Pooled eluates were buffer exchanged into
TBS via spin columns (Amicon® Ultra-4 Centrifugal Filter
Units) and stored at −20 °C. ScFv of size-exclusion chroma-
tography purity grade was used directly for ELISA and
Western Blot characterization methods.
Plate coating
For comparison of PT-Gliadin and different grain di-
gests, 96-well plates (biomat HB) were coated with
100 μl/well of PT-Gliadin dilution ranges (1000, 5000,
250, 125 ng/ml respectively); or digests of wheat, khora-
san wheat (kamut), rye, barley, corn, rice and amaranth
flours (15.0, 7.5, 3.8, 1.9 μg/ml respectively). For all other
ELISA experiments, 96-well plates were coated with
constant concentrations (1000 ng/ml PT-Gliadin or
15 μg/ml of wheat flour, respectively). Plates were coated
with antigens diluted in 20 mM Na2CO3 buffer, pH 9.6
over night at 4 °C. Plates were blocked with 300 μl per
well of 1 % (w/v) PEG 6000 in 20 mM Na2CO3 for 1 h.
Control plates were treated in the same way with the ex-
ception that antigen was omitted. Plates were dried and
stored at room temperature in a dry atmosphere.
Direct ELISA
All sample and antibody dilutions were performed in TBST
buffer (TBS with 0.05 % (v/v) Tween 20) supplemented
with 1 % (v/v) BSA (Albumin solution from bovine serum,
30 % in 0.85 % sodium chloride, Sigma-Aldrich): EDTA-
plasma samples of pre-immune and immunized chicken
were diluted 1000-fold. IgY or scFv (size-exclusion chroma-
tography purity grade) were diluted to 1000, 500, 250, 125,
63, 31 ng/ml.
Samples were added in triplicates (100 μl per well) to
coated and control wells. Plates were incubated for 1 h at
room temperature with agitation at 350 rpm. Plates were
washed four times with 300 μl per well of TBST. 100 μl
per well of goat anti-chicken-IgG (H + L)-HRP antibody
(southern biotech) was added at a 1:3000 dilution. Plates
were incubated for 1 h at room temperature with agitation
at 350 rpm. Plates were washed four times with 300 μl per
well of TBST. 100 μl pre-mixed tetramethybenzidine
(TMB) substrate (Pierce) was added per well and develop-
ing color reaction was stopped with 50 μl of 2 N H2SO4.
Absorbance was measured at 450 nm in a micro plate
reader (GloMax-Multi Detection system, Promega).
For Screening of scFv candidates, bacterial crude
extracts were diluted 10-fold and 50 μl per well was
subjected to coated and control wells, respectively. Plates
were incubated for 1 h at room temperature with
agitation at 350 rpm. Mouse anti-penta-His antibody
(Qiagen) was diluted 250-fold and 50 ng per well was
added to the crude extract dilutions. Plates were incubated
at 350 rpm for 2 h at room temperature. Plates were
washed four times with TBST. Goat anti-mouse-IgG
(H + L)-HRP antibody (southern-biotech) was diluted
1000-fold and 100 ng per well was added. Plates were
incubated at 350 rpm for 1.5 h at room temperature.
Plates were washed four times with 300 μl per well
TBST and ELISA was developed as mentioned above.
Competitive ELISA
All sample and antibody dilutions were performed in
TBST buffer supplemented with 1 % (v/v) BSA.
50 μl per well of Anti-PT-Gliadin IgY at concentra-
tions of ~ 100, 400, 800, 1600 and 3200 μg/ml were
added in triplicates to coated or control wells. Plates
were incubated for 1 h at room temperature with agita-
tion at 350 rpm. 50 μl of scFv was added per well in a ~
0.04 [μg/ml] concentration. Plates were incubated for
40 min at room temperature with agitation at 350 rpm.
Plates were washed four times with 300 μl per well
TBST. 100 μl per well of mouse anti-penta-His antibody
was added at a 1:500 dilution. Plates were incubated for
1 h at room temperature with agitation at 350 rpm and
washed four times with 300 μl per well TBST. 100 μl per
well of goat anti-mouse-IgG-HRP was added in a 1:1000
dilution and plates were incubated for 1 h at room
temperature with agitation at 350 rpm. Plates were
washed four times with TBST. ELISA was developed ac-
cording to direct ELISA.
Western blot
30 μg per lane crude bacterial extracts were separated by
SDS-PAGE (NuPage 12 % Bis Tris Gel, Life technologies)
using EI9001-XCELL II Mini-Cell (Life technologies). Pro-
teins were electrophoretically transferred (Trans-Blot® SD
Semi-Dry Transfer Cell, Bio-Rad) to activated 0.45 μm
PVDF membranes (Life Technologies). Unlike otherwise
noted, all following incubation steps were performed at
room temperature with agitation at 350 rpm: Membranes
were blocked with 3 % (w/v) skim milk powder (Fluka) in
TBS for 1 h. Membranes were incubated simultaneously
with mouse-anti-penta-His antibody (Qiagen) at a 1:500
dilution and mouse-anti-HSP60 (Heat Shock Protein 60,
Mouse monoclonal antibody, Thermo Scientific) at a
1:7500 dilution in TBST supplemented with 1 % milk
powder for 1 h. Membranes were washed twice for
10 min with TBST, followed by incubation in anti-mouse-
IgG-HRP (Amersham ECL Western Blotting Reagent
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Pack, GE healthcare) at a 1:2000 dilution in TBST supple-
mented with 1 % milk powder for 1 h. Membranes were
washed once in TBST and once in TBS. Immunoreactivity
was assessed by incubating membranes in Western Blot
substrate (SuperSignal® West Pico Chemiluminescent
Substrate, Thermo Scientific) using the ECL chemilumin-
escence Western Blot system (Amersham Hyperfilm™
ECL, GE Healthcare).
10 μg per lane PT-Gliadin/ wheat flour digest or 50 μg
per lane digests of wheat, khorasan wheat (kamut), rye,
barley, corn rice and amaranth were separated by SDS-
PAGE, transferred to PVDF membranes and blotted as
described above. Membranes were incubated over night
at +4 °C with scFv (size-exclusion chromatography pur-
ity grade) at a 1:500 dilution (~15 μg/ml), or 1:3000 dilu-
tion (~2.5 μg/l) or IgY at a 1:100000 dilution (~1 μg/ml)
in TBST supplemented with 1 % (w/v) milk powder.
Membranes were washed twice for 10 min with TBST
two times followed by an incubation in goat anti-
chicken-IgG(H + L)-HRP antibody (southern biotech) at
a 1:12000 dilution in TBST supplemented with 1 % milk
powder for 1 h. Membranes were washed once in TBST
and once in TBS. Western Blot was developed as de-
scribed above.
Data evaluation & statistical analysis
ELISA data was analyzed using GraphPad Prism 6
Software. Unlike otherwise noted, data represent mean
values of triplicates with standard error of the mean
(SEM) shown as error bars. For determination of mean
affinity constants, direct ELISA data was analyzed by
3-parameter curve-fit nonlinear regression, OD50 values
were derived for each particular antigen coating concen-
tration. The final mean affinity constant represents the
mean value (+/−SEM) of 4 different calculations: 3
calculated affinity constants at antigen coating ratio
of 2; 1 calculated affinity constants at antigen coating
ratio of 8. Each single calculation of affinity constant
was performed according to the following equation:
Kaff = (n − 1)/2 (n[AB′]t − [AB]t) [26, 27] for coating
with two antigen concentrations [AG]t and [AG’]t and
OD50 values at concentration [AB]t and [AB’]t; n = [AG]t/
[AG’]t and corresponds to antigen coating ratio.
Results
Production of PT-Gliadin reactive chicken IgY
We previously developed an in-house method for the
purification of IgY from yolks of immunized chicken,
which is based on caprylic acid precipitation and subse-
quent PEG-purification. The resulting polyclonal yolk
IgY was tested for binding to PT-Gliadin by ELISA. We
were able to demonstrate concentration -dependent
binding of chicken IgY to PT-Gliadin (Fig. 1). Yolk IgY
served as our control for characterization of PT-Gliadin
reactive scFv.
Production and selection of PT-gliadin reactive scFv
For the production of PT-Gliadin reactive scFvs, we relied
on chicken which were immunized three times and
showed a respectable antibody blood titer (Fig. 2). Chicken
were sacrificed 10–14 days after the third immunization.
Splenic lymphocyte fractions were harvested by ficoll
Fig. 1 IgY binds to PT-Gliadin in a concentration -dependent manner.
Purified yolk IgY was diluted in indicated concentrations and binding
to PT-Gliadin was tested by ELISA as described in Methods. Data
shown are OD (450 nm) values and represent mean values (+/− SEM)
of triplicates
Fig. 2 Anti-PT-Gliadin EDTA-plasma titer of gluten-free raised chicken.
EDTA-plasma from naïve control chicken and chicken one week after
primary, 1st or 2nd booster immunization was analyzed by ELISA as
described in Methods. Data shown are OD (450 nm) values of
three individual chicken displayed as mean values (+/− SEM) of
triplicate measurements
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gradient centrifugation and mononuclear cells were sub-
jected to magnetic beads previously coated with PT-
gliadin. This step was applied to enrich antigen specific B
lymphocytes which bind to PT-Gliadin, coated on beads.
RNA of beads-bound cells was extracted and cDNA was
synthesized. Chicken VH and VL genes were first amplified
by PCR with specific primer pairs, followed by amplifica-
tion in a second PCR step to introduce the linker se-
quence and sites for restriction digestion. These
engineered VH and VL fragments were then ligated into
plasmid vectors to generate VH and VL libraries, respect-
ively. VH and VL fragments were excised from the plas-
mids and ligated into the prokaryotic expression vector
pET28a(+), which provides a C-terminal hexahistidine
tag (Fig. 3). Screening (at least four clones per plate)
revealed that the majority of clones carried correct
scFvs (data not shown). Soluble protein expression
overtime was assessed by western blot (Fig. 4). ScFvs
are soluble expressed in E. coli with increasing target
protein concentration over time. The harvesting time
point was set to 4–5 h post induction for screening
of PT-Gliadin reactive scFvs.
Crude extracts of up to 80 individual bacterial clones
were tested for reactivity to PT-Gliadin by ELISA. Several
crude extracts showed reactivity to PT-Gliadin (Fig. 5).
Screening and protein alignment of these PT-Gliadin react-
ive scFvs revealed an enriched scFv motif. This scFv candi-
date was selected and further characterized in this study.
Purified scFv candidate detects PT-Gliadin and peptic
digested common whole wheat flour in vitro
ScFv candidate was purified to homogeneity by immobi-
lized metal affinity and subsequent size-exclusion chro-
matography. Purified scFv showed concentration
-dependent binding to PT-Gliadin as expected (Fig. 6a).
Binding reached approximate equilibrium after 3 h of in-
cubation time with scFv (Fig. 6c). We questioned
whether scFv would also detect natural wheat antigens,
mimicking the real-life situation. Common whole-wheat
flour was subjected to gastric digestion in form of “simu-
lated gastric fluid” (SGF), to resemble the protein por-
tion that enters the upper intestinal duodenum after
stomach passage. Gastric digested wheat flour, denoted
as “wheat flour digest”, was coated onto 96-ELISA plates
Fig. 3 Schematic view of scFv fragment cloned into the expression vector pET28a (+). VH and VL fragments assemble to full-length scFv in between
the linker peptide and are ligated into pET28a (+) vector, which provides a C-terminal hexahistidine tag
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analogous to PT-Gliadin. Direct ELISA testing revealed
concentration -dependent, specific binding of scFv
(Fig. 6b), reaching approximate equilibrium after 3 h in-
cubation time (Fig. 6d). Furthermore, scFv detects PT-
Gliadin and wheat flour digest under non-reducing and
reducing conditions in western blot, revealing similar
binding patterns compared to IgY (Fig. 7).
Polyclonal anti-PT-Gliadin-IgY competitively displaces
scFv - evidence of a common epitope
Since scFv exerts comparable binding properties to IgY,
we hypothesized that they might have a common epi-
tope. To address this theory, we developed a competitive
ELISA assay, which allows specific detection of scFv via
hexahistidine tag. For competition, IgY dilution range
was pre-incubated for 60 min on coated antigen (PT-
Gliadin or wheat flour digest, respectively). Then, scFv
was added at constant concentration and bound scFv
was detected by anti-penta-His antibody. IgY competi-
tively displaces scFv to a high extent (86 % +/− 0.03 %)
from PT-Gliadin coated plates (Fig. 8a) and almost fully
(94 % +/− 1.14 %) displaces scFv from coated natural
wheat flour (Fig. 8b). This data clearly argue for a com-
mon binding epitope between polyclonal IgY and mono-
clonal scFv, which is accessible in PT-Gliadin and in
digested natural wheat flour in vitro.
ScFv detects gluten-containing grain digests, including
common wheat, khorasan wheat and rye
As we had been able to demonstrate concentration
-dependent, specific binding of scFv to PT-Gliadin and
wheat flour digest, we wanted to assess scFv reactivity to
other grains. Digests of common bread wheat, khorasan
wheat, rye, barley, corn, rice and amaranth were coated
in four protein concentrations onto 96-well ELISA
plates. Four scFv concentrations in the range of 10–
10000 ng/ml were subjected to the four antigen-coating
concentrations by ELISA, and sigmoid binding curves
were analyzed by Graph Pad Prism software. As kinetic
binding experiments revealed that approximate equilib-
rium was reached after a 3 h incubation period with scFv
(6 C and D), the incubation time for binding studies was
adjusted to this incubation time. Sigmoid binding curves
for PT-Gliadin, wheat digest and khorasan wheat digest
were comparable (Fig. 9a, b, c), indicating that wheat
prolamins are successfully targeted by scFv. Accordingly,
scFv detected rye digest (Fig. 9d) to a lower extent than
wheat digest. Notably, scFv did not react with barley
(Fig. 9e), gluten-free grains like corn (Fig. 9f ) and rice
(Fig. 9g), or pseudo-grains like amaranth (Fig. 9h).
ELISA data were further supported by western blot re-
sults, demonstrating scFv binding to PT-Gliadin, wheat
flour digest, khorasan wheat flour digest and to a lesser
degree to rye. On the contrary, scFv exerts no binding
towards barley, corn, rice or amaranth (Fig. 10). Based
on data of sigmoid binding curves, we wanted to calcu-
late rough affinity constants for binding of scFv to PT-
Fig. 4 Expression time course of scFv which is soluble expressed in E. coli BL21/ (DE3). Crude extracts (30 μg protein per lane) from indicated time
points before/after induction with 1 mM IPTG were separated by SDS-PAGE and blotted on PVDF membranes. Western Blot was performed as
described in Methods. The upper lane shows target protein expression, the lower lane (E. coli 60 kDa HSP60 protein) represents the loading control.
Mock represents the negative control (lysates of bacteria transformed with empty vector). Experiment shown is representative for at least three
repeated experiments
Fig. 5 ELISA based testing of scFv candidates for reactivity to PT-Gliadin.
Bacterial crude extracts expressing candidate scFvs were tested for
antigen binding by ELISA as described in Methods. Samples were diluted
10-fold in TBS supplemented with 0.05 % Tween and 1 % BSA. Mock
represents the negative control (crude extracts of bacteria transformed
with empty vector). Data shown are OD (450 nm) levels and represent
mean values (+/− SD) of duplicates
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Fig. 6 Purified scFv detects PT-Gliadin and natural wheat flour digest. a. ScFv binds to PT-Gliadin in a concentration -dependent manner. Purified
scFv was diluted in indicated concentrations and binding was assessed by ELISA as described in Methods. Data shown are OD (450 nm) values and
represent mean values (+/− SEM) of triplicates. b. Purified scFv binds to natural wheat flour digest in a concentration -dependent manner. Purified
scFv was diluted in indicated concentrations and binding was assessed by ELISA as described in Methods. Data shown are OD (450 nm) values and
represent mean values (+/− SEM) of triplicates. c. ScFv binding reaches approximate equilibrium after 3 h incubation time. Two single chain
concentrations (500 and 1000 ng/ml respectively) were incubated for indicated time and binding to (c). PT-Gliadin or (d). wheat flour
digest was assessed by ELISA as described in Methods. Data shown represent OD (450 nm) values at different incubation times compared to the OD
(450 nm) value after 3 h (ODx/OD3h *100). Mean values (+/− SEM) of triplicates are shown
Fig. 7 Purified scFv detects PT-Gliadin and natural wheat flour digest comparable to IgY. PT-Gliadin or wheat flour digest (10 μg per lane) were
separated under reducing [red] or non-reducing [non] conditions on a 12 % Bis-Tris Gel and blotted on activated PVDF membranes. Western Blot
was performed as described in Methods, using purified scFv in 1:500 (~15 μg/ml) or IgY in 1:100000 (~1 μg/ml) dilutions. Control represents a blot
treated in the same way, but where primary antibody was omitted. Experiment shown is representative for at least three repeated experiments
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Gliadin and flour digests. For the calculation we relied
on a method for the assessment of mean affinity con-
stants (Kaffmean) by direct ELISA, first described by
Loomans et al. in 1995 [26]: Affinity constants were cal-
culated based on the scFv concentration at OD50 of each
sigmoid antigen curve. Four scFv concentrations sub-
jected to four antigen-coating concentrations allow three
affinity calculations for an antigen coating ratio of two
and one for an antigen coating ratio of eight. Mean af-
finity constants, shown in Table 1, represent the mean of
four calculated affinity calculations per antigen. ScFv tar-
gets PT-Gliadin, common and khorasan wheat digest
with Kaff mean values in the high nanomolar range;
3.82 (+/−1.93) x 107 M-1, 3.21 (+/− 2.14) x 107 M-1
and 2.30 (+/− 1.49) x 107 M-1; respectively.
Discussion
CD affects approximately 1 % of the population
worldwide [3], with rising incidence in certain geo-
graphic areas explainable by environmental and life
style factors [28].
Much research contributed in solving the puzzle of
celiac disease, which is known today as a multi-
factorial interplay of innate and adaptive immunity. In
short, dietary derived prolamins termed ‘gluten’ break
intestinal epithelial barrier and enter the lamina pro-
pria, where they provoke adverse reactions accom-
plished both by innate and adaptive immune cells.
The only treatment option for CD remains the GFD
which, though successful in most patients, is associ-
ated with substantial social burden, higher nutritional
costs and compliance problems [29]. In some pa-
tients, however, even after long-term adherence to
GFD, CD symptoms and clinical manifestations re-
main [30–32]. Overall, there is urgent need for thera-
peutic regimes complementing or replacing the GFD.
In this study, we present an avian scFv, selected from a
chicken gene library, which targets PT-Gliadin and
natural flour digests of wheat and rye. ScFv was expressed
successful in soluble form in E. coli, purified to homogen-
eity and characterized by biochemical methods. We could
demonstrate concentration -dependent specific binding of
scFv to PT-Gliadin with binding affinities in the high
nanomolar range. ScFv showed similar binding patterns to
PT-Gliadin and wheat flour digest compared to polyclonal
IgY, purified from yolks of immunized chicken. We de-
signed a competitive ELISA experiment to demonstrate
displacement of scFv by IgY, which argues for a common
epitope between scFv and IgY. CD is provoked by dietary
prolamins of the triticeaen grass tribe, including wheat gli-
adin, rye secalin and barley hordein. Strictly speaking,
gliadin denotes the prolamin fraction of wheat. When
referring to toxic celiac entities, however, the term
gluten is used synonymously for noxious prolamins of
different grain origin. By subjecting equal amounts of
different whole grain flours to gastric digestion (by
the aid of SGF, as mentioned in the experimental sec-
tion), we were able to directly compare binding of
scFv to different cereal grains high or devoid of glu-
ten. ScFv shows comparable binding to common
wheat flour and khorasan wheat flour digests. Khora-
san wheat (Triticum turgidum turanicum), traded as
kamut, is considered an ancient relative of modern
durum wheat (pasta wheat) [33]. Previously, it was as-
sumed that ancient wheat strains like khorasan are
devoid or low of celiac toxicity compared to modern
industrial strains. Recent studies demonstrate the lack
of difference between the toxicity of traditional and
modern strains and recommend the total exclusion of
all wheat varieties [33, 34]. Our observation, that scFv tar-
gets both, common bread wheat (Triticum aestivum) and
khorasan wheat (Triticum turgidum turanicum), supports
Fig. 8 IgY competes with scFv for antigen binding sites. a. IgY competitively displaces scFv from PT-Gliadin coated plates. Competitive
ELISA was performed with a 60 min pre-incubation with anti-PT-Gliadin IgY at indicated concentrations followed by addition of anti-PT-Gli-
adin-scFv at a concentration of ~ 0.04 [μg/ml] for 40 min. Detection was performed with anti penta-His antibody, as it detects specifically the His-tag
labelled scFv but does not react with IgY. ELISA principle is described in Methods. Data shown are OD (450 nm) values and represent
mean values (+/−SEM) of triplicates. b. IgY competitively displaces scFv from wheat flour digest coated plates. Competitive ELISA was
performed as described in A and Methods. Data shown are OD (450 nm) values and represent mean values (+/−SEM) of triplicates
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Fig. 9 (See legend on next page.)
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this view. Triticum aestivum is the predominantly used
wheat species in the modern industrialized world, espe-
cially since its high protein content favors baking proper-
ties. It harbors the most immunogenic celiac toxins
[35], though homologous toxic peptides can be found
in rye and barley. Accordingly, scFv detected rye to a
lesser extent than common or khorasan wheat. Not-
ably, scFv failed to detect barley digest in our setting.
Most studies assessing celiac toxicity are focusing on
wheat gluten or digests thereof [36, 37], though im-
mune reactivity to rye and barley was readily demon-
strated in the past [38] and is reflected by the
susceptibility of CD patients to these grain species. A
recent study investigated significant differences in
hordein spectra of different barley varieties, rendering
malting barleys (Hordeum vulgare) less immunogenic
than wild barleys (Hordeum chilense) [39]. In our ex-
perimental setting, six-rowed barley (Hordeum vulgare
hexastichon), a representative of the H. vulgare spe-
cies, was used. To our knowledge, degree of celiac
toxicity has not been investigated explicitly for this
barley subspecies so far. Overall, we assume that our
scFv detects celiac noxious peptides present in sub-
stantial amounts in wheat and rye, but in quantities
below the detection limit in barley. Another possibil-
ity is that the epitope targeted by scFv is present in
wheat and rye digests, but absent or not accessible in
barley digests. Rice and corn represent natural gluten-
free grains and are essential part of the GFD [40].
Conclusively, scFv shows no reactivity towards these
grain species. Recently, pseudo grains like amaranth,
buckwheat and quinoa have entered the stage [41].
They resemble grains though they belong biologically
to a distinct group, and therefore represent a wel-
come dietary alternative for CD patients. As expected,
scFv showed no reactivity to amaranth digest. In sum-
mary, we were able to soluble express a scFv in E.
coli, which exerts specific binding towards PT-Gliadin
and gluten-containing wheat and rye digests, known
to be noxious in terms of CD.
Conclusions
We have successfully cloned and selected a scFv specific
for noxious CD peptides. It has shown in vitro binding
potential to PT-Gliadin and digests of gluten-containing
grains, but exerts no reactivity to gluten-free grains and
pseudo grains. We think that scFv can be of benefit for
future CD treatment regimes.
(See figure on previous page.)
Fig. 9 ScFv binds to digests of gluten-rich grains, but not to gluten-free grains or pseudo grains. ScFv was diluted to 10, 100, 1000 and 10,000 ng/ml
and binding to various grain digests was assessed by ELISA as described in Methods. Data shown were analyzed by 3-parameter curve-fit nonlinear
regression using Graph Pad Prism 6 software and are OD values (450 nm) representing the mean (+/− SEM) of triplicates. ScFv detects PT-Gliadin (a),
common bread wheat (b), khorasan wheat (c) and to lower degree rye (d). ScFv does not react with barley (e), corn (f), or rice (g). ScFv does not detect
the pseudo grain amaranth (h). Please note the axis break in e, f, g and h, which was introduced to demonstrate that OD450 does not exceed 0.2 and
represents background signal
Fig. 10 ScFv detects gluten-rich grain digests in Western Blot. PT-Gliadin (10 μg per lane) or different flour digests (50 μg per lane) were separated
under reducing conditions on a 12 % Bis-Tris Gel and blotted on activated PVDF membranes. Western Blot was performed as described in Methods,
using purified scFv in a 1:3000 (~2.5 μg/ml) dilution. Control represents a blot treated in the same way, but where primary antibody was omitted.
Experiment shown is representative for at least two repeated experiments
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